Baidu
map
DRUG METAB PHARMACOK 润色咨询

Drug Metabolism and Pharmacokinetics

出版年份：2002 年文章数：1076 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：4.2% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1180409, encodeId=1b001180409c0, content=需要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1d92146067, createdName=小油条-Sky, createdTime=Tue Jan 04 14:58:33 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100106, encodeId=9127110010644, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548856, encodeId=5ead548856f4, content=Drug Metabolism and Pharmacokinetics 目前underreview 40多天了，未变更日期，想问一下什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Ne59unJiaEKVBUyCwZltwRbELOF1BLKicIM9qNBT5tmPquVx8JGRz1dyKZtUBRTbwRlg8dV8lR4KvKQPr6CNFvHpic/0, createdBy=976d1603886, createdName=Shan3, createdTime=Fri Nov 03 09:17:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519091, encodeId=7f39519091e2, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：与大家分享投稿经验，供参考。 <br> 2015年9月18日投稿 with editor <br> 10月16日 under review <br> 10月27日 变更一次under review <br> 11月11日 再次变更under review（猜测是每次变更审稿人） <br> 11月16日 under editor evaluation <br> 12月03日 decision in process <br> 12月04日 revise <br> 12月19日 revision submitted to journal <br> 12月21日 with editor <br> 12月22日 under review <br> 2016年1月13日 decision in process <br> 1月15日 accept <br> 1月18日 final accept <br> <br> <br> <br> <br> <br> <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=352, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae271686324, createdName=胡大虾, createdTime=Sat Feb 06 23:17:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517618, encodeId=02e951e618a9, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：年底了 进度慢下来了 但整体不错 提供大家投稿链接http://ees.elsevier.com/dmpk/default.asp, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f41631383, createdName=Bradley, createdTime=Wed Dec 16 14:57:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517577, encodeId=fb8551e57786, content=求投稿链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af651630166, createdName=happyqingya, createdTime=Mon Dec 14 10:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505802, encodeId=371250580287, content=各位大侠，我想问一下“Drug Metabolism and Pharmacokinetics”这个杂志的投稿系统在哪里呀？网上没找到呀，请指点，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Sep 03 09:10:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504528, encodeId=af1c5045283e, content=总体来说，形式是比较看好的，今年快到3分左右，比去年高了不少，明年应该能达到3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=431, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiming, createdTime=Wed Jul 30 12:55:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=496836, encodeId=273b4968361b, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：审稿很快，也比较容易接收，时间不太多的可以考虑~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Jun 27 10:36:00 CST 2013, time=2013-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=486668, encodeId=671f48666826, content=审稿速度:1.0<br>经验分享：审稿速度快，约20天。方向是药物代谢和药物动力学，以前发过其他方向的文章，现在好像只收药物代谢和动力学的文章。我投的是基础药理的，直接被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf7955666, createdName=medication, createdTime=Mon Feb 13 13:54:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2022-01-04 小油条-Sky

    需要版面费吗？

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1180409, encodeId=1b001180409c0, content=需要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1d92146067, createdName=小油条-Sky, createdTime=Tue Jan 04 14:58:33 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100106, encodeId=9127110010644, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548856, encodeId=5ead548856f4, content=Drug Metabolism and Pharmacokinetics 目前underreview 40多天了，未变更日期，想问一下什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Ne59unJiaEKVBUyCwZltwRbELOF1BLKicIM9qNBT5tmPquVx8JGRz1dyKZtUBRTbwRlg8dV8lR4KvKQPr6CNFvHpic/0, createdBy=976d1603886, createdName=Shan3, createdTime=Fri Nov 03 09:17:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519091, encodeId=7f39519091e2, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：与大家分享投稿经验，供参考。 <br> 2015年9月18日投稿 with editor <br> 10月16日 under review <br> 10月27日 变更一次under review <br> 11月11日 再次变更under review（猜测是每次变更审稿人） <br> 11月16日 under editor evaluation <br> 12月03日 decision in process <br> 12月04日 revise <br> 12月19日 revision submitted to journal <br> 12月21日 with editor <br> 12月22日 under review <br> 2016年1月13日 decision in process <br> 1月15日 accept <br> 1月18日 final accept <br> <br> <br> <br> <br> <br> <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=352, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae271686324, createdName=胡大虾, createdTime=Sat Feb 06 23:17:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517618, encodeId=02e951e618a9, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：年底了 进度慢下来了 但整体不错 提供大家投稿链接http://ees.elsevier.com/dmpk/default.asp, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f41631383, createdName=Bradley, createdTime=Wed Dec 16 14:57:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517577, encodeId=fb8551e57786, content=求投稿链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af651630166, createdName=happyqingya, createdTime=Mon Dec 14 10:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505802, encodeId=371250580287, content=各位大侠，我想问一下“Drug Metabolism and Pharmacokinetics”这个杂志的投稿系统在哪里呀？网上没找到呀，请指点，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Sep 03 09:10:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504528, encodeId=af1c5045283e, content=总体来说，形式是比较看好的，今年快到3分左右，比去年高了不少，明年应该能达到3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=431, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiming, createdTime=Wed Jul 30 12:55:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=496836, encodeId=273b4968361b, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：审稿很快，也比较容易接收，时间不太多的可以考虑~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Jun 27 10:36:00 CST 2013, time=2013-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=486668, encodeId=671f48666826, content=审稿速度:1.0<br>经验分享：审稿速度快，约20天。方向是药物代谢和药物动力学，以前发过其他方向的文章，现在好像只收药物代谢和动力学的文章。我投的是基础药理的，直接被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf7955666, createdName=medication, createdTime=Mon Feb 13 13:54:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2021-12-29 小动量

    ORCIDID是什么？怎么注册？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1180409, encodeId=1b001180409c0, content=需要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1d92146067, createdName=小油条-Sky, createdTime=Tue Jan 04 14:58:33 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100106, encodeId=9127110010644, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548856, encodeId=5ead548856f4, content=Drug Metabolism and Pharmacokinetics 目前underreview 40多天了，未变更日期，想问一下什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Ne59unJiaEKVBUyCwZltwRbELOF1BLKicIM9qNBT5tmPquVx8JGRz1dyKZtUBRTbwRlg8dV8lR4KvKQPr6CNFvHpic/0, createdBy=976d1603886, createdName=Shan3, createdTime=Fri Nov 03 09:17:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519091, encodeId=7f39519091e2, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：与大家分享投稿经验，供参考。 <br> 2015年9月18日投稿 with editor <br> 10月16日 under review <br> 10月27日 变更一次under review <br> 11月11日 再次变更under review（猜测是每次变更审稿人） <br> 11月16日 under editor evaluation <br> 12月03日 decision in process <br> 12月04日 revise <br> 12月19日 revision submitted to journal <br> 12月21日 with editor <br> 12月22日 under review <br> 2016年1月13日 decision in process <br> 1月15日 accept <br> 1月18日 final accept <br> <br> <br> <br> <br> <br> <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=352, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae271686324, createdName=胡大虾, createdTime=Sat Feb 06 23:17:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517618, encodeId=02e951e618a9, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：年底了 进度慢下来了 但整体不错 提供大家投稿链接http://ees.elsevier.com/dmpk/default.asp, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f41631383, createdName=Bradley, createdTime=Wed Dec 16 14:57:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517577, encodeId=fb8551e57786, content=求投稿链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af651630166, createdName=happyqingya, createdTime=Mon Dec 14 10:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505802, encodeId=371250580287, content=各位大侠，我想问一下“Drug Metabolism and Pharmacokinetics”这个杂志的投稿系统在哪里呀？网上没找到呀，请指点，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Sep 03 09:10:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504528, encodeId=af1c5045283e, content=总体来说，形式是比较看好的，今年快到3分左右，比去年高了不少，明年应该能达到3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=431, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiming, createdTime=Wed Jul 30 12:55:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=496836, encodeId=273b4968361b, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：审稿很快，也比较容易接收，时间不太多的可以考虑~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Jun 27 10:36:00 CST 2013, time=2013-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=486668, encodeId=671f48666826, content=审稿速度:1.0<br>经验分享：审稿速度快，约20天。方向是药物代谢和药物动力学，以前发过其他方向的文章，现在好像只收药物代谢和动力学的文章。我投的是基础药理的，直接被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf7955666, createdName=medication, createdTime=Mon Feb 13 13:54:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2017-11-03 Shan3

    Drug Metabolism and Pharmacokinetics 目前underreview 40多天了，未变更日期，想问一下什么情况

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1180409, encodeId=1b001180409c0, content=需要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1d92146067, createdName=小油条-Sky, createdTime=Tue Jan 04 14:58:33 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100106, encodeId=9127110010644, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548856, encodeId=5ead548856f4, content=Drug Metabolism and Pharmacokinetics 目前underreview 40多天了，未变更日期，想问一下什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Ne59unJiaEKVBUyCwZltwRbELOF1BLKicIM9qNBT5tmPquVx8JGRz1dyKZtUBRTbwRlg8dV8lR4KvKQPr6CNFvHpic/0, createdBy=976d1603886, createdName=Shan3, createdTime=Fri Nov 03 09:17:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519091, encodeId=7f39519091e2, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：与大家分享投稿经验，供参考。 <br> 2015年9月18日投稿 with editor <br> 10月16日 under review <br> 10月27日 变更一次under review <br> 11月11日 再次变更under review（猜测是每次变更审稿人） <br> 11月16日 under editor evaluation <br> 12月03日 decision in process <br> 12月04日 revise <br> 12月19日 revision submitted to journal <br> 12月21日 with editor <br> 12月22日 under review <br> 2016年1月13日 decision in process <br> 1月15日 accept <br> 1月18日 final accept <br> <br> <br> <br> <br> <br> <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=352, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae271686324, createdName=胡大虾, createdTime=Sat Feb 06 23:17:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517618, encodeId=02e951e618a9, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：年底了 进度慢下来了 但整体不错 提供大家投稿链接http://ees.elsevier.com/dmpk/default.asp, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f41631383, createdName=Bradley, createdTime=Wed Dec 16 14:57:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517577, encodeId=fb8551e57786, content=求投稿链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af651630166, createdName=happyqingya, createdTime=Mon Dec 14 10:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505802, encodeId=371250580287, content=各位大侠，我想问一下“Drug Metabolism and Pharmacokinetics”这个杂志的投稿系统在哪里呀？网上没找到呀，请指点，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Sep 03 09:10:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504528, encodeId=af1c5045283e, content=总体来说，形式是比较看好的，今年快到3分左右，比去年高了不少，明年应该能达到3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=431, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiming, createdTime=Wed Jul 30 12:55:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=496836, encodeId=273b4968361b, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：审稿很快，也比较容易接收，时间不太多的可以考虑~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Jun 27 10:36:00 CST 2013, time=2013-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=486668, encodeId=671f48666826, content=审稿速度:1.0<br>经验分享：审稿速度快，约20天。方向是药物代谢和药物动力学，以前发过其他方向的文章，现在好像只收药物代谢和动力学的文章。我投的是基础药理的，直接被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf7955666, createdName=medication, createdTime=Mon Feb 13 13:54:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2016-02-06 胡大虾

    审稿速度:6.0 | 投稿命中率:50.0
    经验分享：与大家分享投稿经验，供参考。
    2015年9月18日投稿 with editor
    10月16日 under review
    10月27日 变更一次under review
    11月11日 再次变更under review（猜测是每次变更审稿人）
    11月16日 under editor evaluation
    12月03日 decision in process
    12月04日 revise
    12月19日 revision submitted to journal
    12月21日 with editor
    12月22日 under review
    2016年1月13日 decision in process
    1月15日 accept
    1月18日 final accept






    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1180409, encodeId=1b001180409c0, content=需要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1d92146067, createdName=小油条-Sky, createdTime=Tue Jan 04 14:58:33 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100106, encodeId=9127110010644, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548856, encodeId=5ead548856f4, content=Drug Metabolism and Pharmacokinetics 目前underreview 40多天了，未变更日期，想问一下什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Ne59unJiaEKVBUyCwZltwRbELOF1BLKicIM9qNBT5tmPquVx8JGRz1dyKZtUBRTbwRlg8dV8lR4KvKQPr6CNFvHpic/0, createdBy=976d1603886, createdName=Shan3, createdTime=Fri Nov 03 09:17:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519091, encodeId=7f39519091e2, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：与大家分享投稿经验，供参考。 <br> 2015年9月18日投稿 with editor <br> 10月16日 under review <br> 10月27日 变更一次under review <br> 11月11日 再次变更under review（猜测是每次变更审稿人） <br> 11月16日 under editor evaluation <br> 12月03日 decision in process <br> 12月04日 revise <br> 12月19日 revision submitted to journal <br> 12月21日 with editor <br> 12月22日 under review <br> 2016年1月13日 decision in process <br> 1月15日 accept <br> 1月18日 final accept <br> <br> <br> <br> <br> <br> <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=352, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae271686324, createdName=胡大虾, createdTime=Sat Feb 06 23:17:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517618, encodeId=02e951e618a9, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：年底了 进度慢下来了 但整体不错 提供大家投稿链接http://ees.elsevier.com/dmpk/default.asp, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f41631383, createdName=Bradley, createdTime=Wed Dec 16 14:57:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517577, encodeId=fb8551e57786, content=求投稿链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af651630166, createdName=happyqingya, createdTime=Mon Dec 14 10:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505802, encodeId=371250580287, content=各位大侠，我想问一下“Drug Metabolism and Pharmacokinetics”这个杂志的投稿系统在哪里呀？网上没找到呀，请指点，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Sep 03 09:10:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504528, encodeId=af1c5045283e, content=总体来说，形式是比较看好的，今年快到3分左右，比去年高了不少，明年应该能达到3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=431, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiming, createdTime=Wed Jul 30 12:55:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=496836, encodeId=273b4968361b, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：审稿很快，也比较容易接收，时间不太多的可以考虑~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Jun 27 10:36:00 CST 2013, time=2013-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=486668, encodeId=671f48666826, content=审稿速度:1.0<br>经验分享：审稿速度快，约20天。方向是药物代谢和药物动力学，以前发过其他方向的文章，现在好像只收药物代谢和动力学的文章。我投的是基础药理的，直接被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf7955666, createdName=medication, createdTime=Mon Feb 13 13:54:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2015-12-16 Bradley

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享：年底了 进度慢下来了 但整体不错 提供大家投稿链接http://ees.elsevier.com/dmpk/default.asp

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1180409, encodeId=1b001180409c0, content=需要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1d92146067, createdName=小油条-Sky, createdTime=Tue Jan 04 14:58:33 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100106, encodeId=9127110010644, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548856, encodeId=5ead548856f4, content=Drug Metabolism and Pharmacokinetics 目前underreview 40多天了，未变更日期，想问一下什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Ne59unJiaEKVBUyCwZltwRbELOF1BLKicIM9qNBT5tmPquVx8JGRz1dyKZtUBRTbwRlg8dV8lR4KvKQPr6CNFvHpic/0, createdBy=976d1603886, createdName=Shan3, createdTime=Fri Nov 03 09:17:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519091, encodeId=7f39519091e2, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：与大家分享投稿经验，供参考。 <br> 2015年9月18日投稿 with editor <br> 10月16日 under review <br> 10月27日 变更一次under review <br> 11月11日 再次变更under review（猜测是每次变更审稿人） <br> 11月16日 under editor evaluation <br> 12月03日 decision in process <br> 12月04日 revise <br> 12月19日 revision submitted to journal <br> 12月21日 with editor <br> 12月22日 under review <br> 2016年1月13日 decision in process <br> 1月15日 accept <br> 1月18日 final accept <br> <br> <br> <br> <br> <br> <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=352, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae271686324, createdName=胡大虾, createdTime=Sat Feb 06 23:17:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517618, encodeId=02e951e618a9, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：年底了 进度慢下来了 但整体不错 提供大家投稿链接http://ees.elsevier.com/dmpk/default.asp, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f41631383, createdName=Bradley, createdTime=Wed Dec 16 14:57:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517577, encodeId=fb8551e57786, content=求投稿链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af651630166, createdName=happyqingya, createdTime=Mon Dec 14 10:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505802, encodeId=371250580287, content=各位大侠，我想问一下“Drug Metabolism and Pharmacokinetics”这个杂志的投稿系统在哪里呀？网上没找到呀，请指点，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Sep 03 09:10:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504528, encodeId=af1c5045283e, content=总体来说，形式是比较看好的，今年快到3分左右，比去年高了不少，明年应该能达到3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=431, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiming, createdTime=Wed Jul 30 12:55:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=496836, encodeId=273b4968361b, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：审稿很快，也比较容易接收，时间不太多的可以考虑~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Jun 27 10:36:00 CST 2013, time=2013-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=486668, encodeId=671f48666826, content=审稿速度:1.0<br>经验分享：审稿速度快，约20天。方向是药物代谢和药物动力学，以前发过其他方向的文章，现在好像只收药物代谢和动力学的文章。我投的是基础药理的，直接被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf7955666, createdName=medication, createdTime=Mon Feb 13 13:54:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2015-12-14 happyqingya

    求投稿链接

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1180409, encodeId=1b001180409c0, content=需要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1d92146067, createdName=小油条-Sky, createdTime=Tue Jan 04 14:58:33 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100106, encodeId=9127110010644, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548856, encodeId=5ead548856f4, content=Drug Metabolism and Pharmacokinetics 目前underreview 40多天了，未变更日期，想问一下什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Ne59unJiaEKVBUyCwZltwRbELOF1BLKicIM9qNBT5tmPquVx8JGRz1dyKZtUBRTbwRlg8dV8lR4KvKQPr6CNFvHpic/0, createdBy=976d1603886, createdName=Shan3, createdTime=Fri Nov 03 09:17:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519091, encodeId=7f39519091e2, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：与大家分享投稿经验，供参考。 <br> 2015年9月18日投稿 with editor <br> 10月16日 under review <br> 10月27日 变更一次under review <br> 11月11日 再次变更under review（猜测是每次变更审稿人） <br> 11月16日 under editor evaluation <br> 12月03日 decision in process <br> 12月04日 revise <br> 12月19日 revision submitted to journal <br> 12月21日 with editor <br> 12月22日 under review <br> 2016年1月13日 decision in process <br> 1月15日 accept <br> 1月18日 final accept <br> <br> <br> <br> <br> <br> <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=352, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae271686324, createdName=胡大虾, createdTime=Sat Feb 06 23:17:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517618, encodeId=02e951e618a9, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：年底了 进度慢下来了 但整体不错 提供大家投稿链接http://ees.elsevier.com/dmpk/default.asp, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f41631383, createdName=Bradley, createdTime=Wed Dec 16 14:57:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517577, encodeId=fb8551e57786, content=求投稿链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af651630166, createdName=happyqingya, createdTime=Mon Dec 14 10:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505802, encodeId=371250580287, content=各位大侠，我想问一下“Drug Metabolism and Pharmacokinetics”这个杂志的投稿系统在哪里呀？网上没找到呀，请指点，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Sep 03 09:10:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504528, encodeId=af1c5045283e, content=总体来说，形式是比较看好的，今年快到3分左右，比去年高了不少，明年应该能达到3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=431, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiming, createdTime=Wed Jul 30 12:55:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=496836, encodeId=273b4968361b, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：审稿很快，也比较容易接收，时间不太多的可以考虑~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Jun 27 10:36:00 CST 2013, time=2013-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=486668, encodeId=671f48666826, content=审稿速度:1.0<br>经验分享：审稿速度快，约20天。方向是药物代谢和药物动力学，以前发过其他方向的文章，现在好像只收药物代谢和动力学的文章。我投的是基础药理的，直接被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf7955666, createdName=medication, createdTime=Mon Feb 13 13:54:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2014-09-03 匿名用户

    各位大侠，我想问一下“Drug Metabolism and Pharmacokinetics”这个杂志的投稿系统在哪里呀？网上没找到呀，请指点，谢谢！

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1180409, encodeId=1b001180409c0, content=需要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1d92146067, createdName=小油条-Sky, createdTime=Tue Jan 04 14:58:33 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100106, encodeId=9127110010644, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548856, encodeId=5ead548856f4, content=Drug Metabolism and Pharmacokinetics 目前underreview 40多天了，未变更日期，想问一下什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Ne59unJiaEKVBUyCwZltwRbELOF1BLKicIM9qNBT5tmPquVx8JGRz1dyKZtUBRTbwRlg8dV8lR4KvKQPr6CNFvHpic/0, createdBy=976d1603886, createdName=Shan3, createdTime=Fri Nov 03 09:17:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519091, encodeId=7f39519091e2, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：与大家分享投稿经验，供参考。 <br> 2015年9月18日投稿 with editor <br> 10月16日 under review <br> 10月27日 变更一次under review <br> 11月11日 再次变更under review（猜测是每次变更审稿人） <br> 11月16日 under editor evaluation <br> 12月03日 decision in process <br> 12月04日 revise <br> 12月19日 revision submitted to journal <br> 12月21日 with editor <br> 12月22日 under review <br> 2016年1月13日 decision in process <br> 1月15日 accept <br> 1月18日 final accept <br> <br> <br> <br> <br> <br> <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=352, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae271686324, createdName=胡大虾, createdTime=Sat Feb 06 23:17:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517618, encodeId=02e951e618a9, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：年底了 进度慢下来了 但整体不错 提供大家投稿链接http://ees.elsevier.com/dmpk/default.asp, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f41631383, createdName=Bradley, createdTime=Wed Dec 16 14:57:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517577, encodeId=fb8551e57786, content=求投稿链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af651630166, createdName=happyqingya, createdTime=Mon Dec 14 10:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505802, encodeId=371250580287, content=各位大侠，我想问一下“Drug Metabolism and Pharmacokinetics”这个杂志的投稿系统在哪里呀？网上没找到呀，请指点，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Sep 03 09:10:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504528, encodeId=af1c5045283e, content=总体来说，形式是比较看好的，今年快到3分左右，比去年高了不少，明年应该能达到3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=431, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiming, createdTime=Wed Jul 30 12:55:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=496836, encodeId=273b4968361b, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：审稿很快，也比较容易接收，时间不太多的可以考虑~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Jun 27 10:36:00 CST 2013, time=2013-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=486668, encodeId=671f48666826, content=审稿速度:1.0<br>经验分享：审稿速度快，约20天。方向是药物代谢和药物动力学，以前发过其他方向的文章，现在好像只收药物代谢和动力学的文章。我投的是基础药理的，直接被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf7955666, createdName=medication, createdTime=Mon Feb 13 13:54:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2014-07-30 qiming

    总体来说，形式是比较看好的，今年快到3分左右，比去年高了不少，明年应该能达到3分

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1180409, encodeId=1b001180409c0, content=需要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1d92146067, createdName=小油条-Sky, createdTime=Tue Jan 04 14:58:33 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100106, encodeId=9127110010644, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548856, encodeId=5ead548856f4, content=Drug Metabolism and Pharmacokinetics 目前underreview 40多天了，未变更日期，想问一下什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Ne59unJiaEKVBUyCwZltwRbELOF1BLKicIM9qNBT5tmPquVx8JGRz1dyKZtUBRTbwRlg8dV8lR4KvKQPr6CNFvHpic/0, createdBy=976d1603886, createdName=Shan3, createdTime=Fri Nov 03 09:17:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519091, encodeId=7f39519091e2, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：与大家分享投稿经验，供参考。 <br> 2015年9月18日投稿 with editor <br> 10月16日 under review <br> 10月27日 变更一次under review <br> 11月11日 再次变更under review（猜测是每次变更审稿人） <br> 11月16日 under editor evaluation <br> 12月03日 decision in process <br> 12月04日 revise <br> 12月19日 revision submitted to journal <br> 12月21日 with editor <br> 12月22日 under review <br> 2016年1月13日 decision in process <br> 1月15日 accept <br> 1月18日 final accept <br> <br> <br> <br> <br> <br> <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=352, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae271686324, createdName=胡大虾, createdTime=Sat Feb 06 23:17:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517618, encodeId=02e951e618a9, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：年底了 进度慢下来了 但整体不错 提供大家投稿链接http://ees.elsevier.com/dmpk/default.asp, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f41631383, createdName=Bradley, createdTime=Wed Dec 16 14:57:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517577, encodeId=fb8551e57786, content=求投稿链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af651630166, createdName=happyqingya, createdTime=Mon Dec 14 10:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505802, encodeId=371250580287, content=各位大侠，我想问一下“Drug Metabolism and Pharmacokinetics”这个杂志的投稿系统在哪里呀？网上没找到呀，请指点，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Sep 03 09:10:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504528, encodeId=af1c5045283e, content=总体来说，形式是比较看好的，今年快到3分左右，比去年高了不少，明年应该能达到3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=431, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiming, createdTime=Wed Jul 30 12:55:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=496836, encodeId=273b4968361b, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：审稿很快，也比较容易接收，时间不太多的可以考虑~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Jun 27 10:36:00 CST 2013, time=2013-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=486668, encodeId=671f48666826, content=审稿速度:1.0<br>经验分享：审稿速度快，约20天。方向是药物代谢和药物动力学，以前发过其他方向的文章，现在好像只收药物代谢和动力学的文章。我投的是基础药理的，直接被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf7955666, createdName=medication, createdTime=Mon Feb 13 13:54:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2013-06-27 匿名用户

    审稿速度:1.0 | 投稿命中率:75.0
    经验分享：审稿很快，也比较容易接收，时间不太多的可以考虑~

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1180409, encodeId=1b001180409c0, content=需要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1d92146067, createdName=小油条-Sky, createdTime=Tue Jan 04 14:58:33 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1100106, encodeId=9127110010644, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548856, encodeId=5ead548856f4, content=Drug Metabolism and Pharmacokinetics 目前underreview 40多天了，未变更日期，想问一下什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=325, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Ne59unJiaEKVBUyCwZltwRbELOF1BLKicIM9qNBT5tmPquVx8JGRz1dyKZtUBRTbwRlg8dV8lR4KvKQPr6CNFvHpic/0, createdBy=976d1603886, createdName=Shan3, createdTime=Fri Nov 03 09:17:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519091, encodeId=7f39519091e2, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：与大家分享投稿经验，供参考。 <br> 2015年9月18日投稿 with editor <br> 10月16日 under review <br> 10月27日 变更一次under review <br> 11月11日 再次变更under review（猜测是每次变更审稿人） <br> 11月16日 under editor evaluation <br> 12月03日 decision in process <br> 12月04日 revise <br> 12月19日 revision submitted to journal <br> 12月21日 with editor <br> 12月22日 under review <br> 2016年1月13日 decision in process <br> 1月15日 accept <br> 1月18日 final accept <br> <br> <br> <br> <br> <br> <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=352, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae271686324, createdName=胡大虾, createdTime=Sat Feb 06 23:17:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517618, encodeId=02e951e618a9, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：年底了 进度慢下来了 但整体不错 提供大家投稿链接http://ees.elsevier.com/dmpk/default.asp, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f41631383, createdName=Bradley, createdTime=Wed Dec 16 14:57:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=517577, encodeId=fb8551e57786, content=求投稿链接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af651630166, createdName=happyqingya, createdTime=Mon Dec 14 10:32:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505802, encodeId=371250580287, content=各位大侠，我想问一下“Drug Metabolism and Pharmacokinetics”这个杂志的投稿系统在哪里呀？网上没找到呀，请指点，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Sep 03 09:10:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504528, encodeId=af1c5045283e, content=总体来说，形式是比较看好的，今年快到3分左右，比去年高了不少，明年应该能达到3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=431, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiming, createdTime=Wed Jul 30 12:55:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=496836, encodeId=273b4968361b, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：审稿很快，也比较容易接收，时间不太多的可以考虑~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Jun 27 10:36:00 CST 2013, time=2013-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=486668, encodeId=671f48666826, content=审稿速度:1.0<br>经验分享：审稿速度快，约20天。方向是药物代谢和药物动力学，以前发过其他方向的文章，现在好像只收药物代谢和动力学的文章。我投的是基础药理的，直接被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf7955666, createdName=medication, createdTime=Mon Feb 13 13:54:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2012-02-13 medication

    审稿速度:1.0
    经验分享：审稿速度快，约20天。方向是药物代谢和药物动力学，以前发过其他方向的文章，现在好像只收药物代谢和动力学的文章。我投的是基础药理的，直接被拒。

    0

共13条页码: 1/2页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map